ClinicalTrials.govpublic full text
Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial
kidney disease, radiation nephropathy, metastatic castrate resistant prostate cancer (mcrpc), mcrpc, 177lutetium, 177lu-psma, radioligand therapy, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1032960
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.